FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310421796> ?p ?o ?g. }

• W4310421796 endingPage "e2244343" @default.
• W4310421796 startingPage "e2244343" @default.
• W4310421796 abstract "Importance Mailing human papillomavirus (HPV) self-sampling kits increases cervical cancer screening participation, but effects may differ across subpopulations. Subpopulation data can inform US health care system implementation. Objective To identify patient characteristics that modify effectiveness of a mailed kit intervention at increasing screening. Design, Setting, and Participants This was a secondary analysis of data from the Home-Based Options to Make Cervical Cancer Screening Easy (HOME) randomized clinical trial conducted from 2014 to 2018 at Kaiser Permanente Washington. Data analysis was performed from March 2018 to May 2022. Individuals aged 30 to 64 years with female sex, health plan enrollment longer than 3 years and 5 months, a current primary care clinician, and no Papanicolaou test within the prior 3 years and 5 months were identified through electronic medical records and randomized (1:1) to the control or intervention group. Interventions The control group received usual care Papanicolaou screening reminders and outreach. The intervention group received usual care plus an unsolicited mailed HPV self-sampling kit. Main Outcomes and Measures Screening uptake was captured within 6 months after randomization. Baseline patient characteristics (age, race, ethnicity, travel time to clinic, income, body mass index, tobacco use, health plan enrollment duration, time since last Papanicolaou test, mammography, comorbidities, and colorectal cancer screening adherence) were extracted from the electronic medical record. Results Of 19 734 individuals (mean [SD] age, 50.1 [9.5] years; 14 129 [71.6%] White), 9843 were randomized to the intervention group, and 9891 were randomized to the control group. Screening uptake was 26.3% (2592 of 9843 individuals) in the intervention group vs 17.4% (1719 of 9891 individuals) in the control group (relative risk [RR], 1.51; 95% CI, 1.43-1.60). Although absolute differences in uptake by group varied little by screening history, relative effects were greater with longer vs shorter time since last Papanicolaou test (no prior Papanicolaou test: RRs, 1.85-3.25; ≥10 years: RR, 2.78; 5-10 years: RRs, 1.69-1.86; &amp;lt;5 years: RRs 1.29-1.37). Relative effects were greater in participants overdue (RR, 2.03; 95% CI, 1.73-2.38) vs up-to-date with mammography (RR, 1.53; 95% CI, 1.41-1.67), although absolute difference was greater in the up-to-date group. Differences by age were not significant, with RRs of 1.33 to 1.48 across 5-year age groups in participants 30 to 54, vs 1.60 (95% CI, 1.40-1.82) in participants 55 to 59 and 1.77 (95% CI, 1.56-2.01) in participants 60 to 64 years. Among those mailed kits, there were differences in kit use vs in-clinic screening by age, race, plan enrollment duration, underscreening duration, and colorectal cancer screening adherence. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, clinically important improvements in screening uptake were observed for all subgroups. Differences in magnitude of intervention effect and kit use highlighted opportunities to optimize HPV self-sampling for priority groups. Trial Registration ClinicalTrials.gov Identifier: NCT02005510" @default.
• W4310421796 created "2022-12-10" @default.
• W4310421796 creator A5001177354 @default.
• W4310421796 creator A5001413990 @default.
• W4310421796 creator A5028039350 @default.
• W4310421796 creator A5030172732 @default.
• W4310421796 creator A5042391078 @default.
• W4310421796 creator A5050357899 @default.
• W4310421796 creator A5077710776 @default.
• W4310421796 creator A5091113735 @default.
• W4310421796 creator A5091351028 @default.
• W4310421796 date "2022-11-30" @default.
• W4310421796 modified "2023-09-26" @default.
• W4310421796 title "Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit" @default.
• W4310421796 cites W1028759624 @default.
• W4310421796 cites W183724077 @default.
• W4310421796 cites W1931781407 @default.
• W4310421796 cites W1962739454 @default.
• W4310421796 cites W1972487158 @default.
• W4310421796 cites W1975904222 @default.
• W4310421796 cites W1984232879 @default.
• W4310421796 cites W1992984743 @default.
• W4310421796 cites W2004590309 @default.
• W4310421796 cites W2007909376 @default.
• W4310421796 cites W2026946798 @default.
• W4310421796 cites W2049103906 @default.
• W4310421796 cites W2057323348 @default.
• W4310421796 cites W2058892711 @default.
• W4310421796 cites W2060060958 @default.
• W4310421796 cites W2077638076 @default.
• W4310421796 cites W2090719000 @default.
• W4310421796 cites W2101508962 @default.
• W4310421796 cites W2107011177 @default.
• W4310421796 cites W2124460872 @default.
• W4310421796 cites W2129168200 @default.
• W4310421796 cites W2132093724 @default.
• W4310421796 cites W2135495069 @default.
• W4310421796 cites W2142563012 @default.
• W4310421796 cites W214332893 @default.
• W4310421796 cites W2144019179 @default.
• W4310421796 cites W2148836421 @default.
• W4310421796 cites W2189916683 @default.
• W4310421796 cites W2263339089 @default.
• W4310421796 cites W2316234614 @default.
• W4310421796 cites W2336843334 @default.
• W4310421796 cites W2433575101 @default.
• W4310421796 cites W2548044925 @default.
• W4310421796 cites W2550479496 @default.
• W4310421796 cites W2568723751 @default.
• W4310421796 cites W2612526057 @default.
• W4310421796 cites W2613034313 @default.
• W4310421796 cites W2766937701 @default.
• W4310421796 cites W2803053780 @default.
• W4310421796 cites W2809325972 @default.
• W4310421796 cites W2832434163 @default.
• W4310421796 cites W2886124959 @default.
• W4310421796 cites W2902810541 @default.
• W4310421796 cites W2905220860 @default.
• W4310421796 cites W2909340392 @default.
• W4310421796 cites W2910709065 @default.
• W4310421796 cites W2929905027 @default.
• W4310421796 cites W2943723013 @default.
• W4310421796 cites W2946331436 @default.
• W4310421796 cites W2986018635 @default.
• W4310421796 cites W2987729866 @default.
• W4310421796 cites W2999417355 @default.
• W4310421796 cites W3011643157 @default.
• W4310421796 cites W3016913587 @default.
• W4310421796 cites W3038700989 @default.
• W4310421796 cites W3045996770 @default.
• W4310421796 cites W3115252188 @default.
• W4310421796 cites W3116659574 @default.
• W4310421796 cites W3121122407 @default.
• W4310421796 cites W3144761155 @default.
• W4310421796 cites W3207894119 @default.
• W4310421796 cites W3212444018 @default.
• W4310421796 cites W3214524988 @default.
• W4310421796 cites W3215551430 @default.
• W4310421796 cites W3216381949 @default.
• W4310421796 cites W3217502871 @default.
• W4310421796 cites W4205267628 @default.
• W4310421796 cites W4226034403 @default.
• W4310421796 cites W4226190389 @default.
• W4310421796 cites W4226488070 @default.
• W4310421796 cites W4231576061 @default.
• W4310421796 cites W4233275607 @default.
• W4310421796 cites W4237927509 @default.
• W4310421796 cites W4253099211 @default.
• W4310421796 cites W4213393434 @default.
• W4310421796 doi "https://doi.org/10.1001/jamanetworkopen.2022.44343" @default.
• W4310421796 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36449291" @default.
• W4310421796 hasPublicationYear "2022" @default.
• W4310421796 type Work @default.
• W4310421796 citedByCount "1" @default.
• W4310421796 countsByYear W43104217962023 @default.
• W4310421796 crossrefType "journal-article" @default.
• W4310421796 hasAuthorship W4310421796A5001177354 @default.
• W4310421796 hasAuthorship W4310421796A5001413990 @default.

• next